# Advancements in Alzheimer's blood test detection

> Live situation record from CLSTR: https://clstr.news/situations/advancements-in-alzheimers-blood-test-detection
> Updated: 2026-08-26T13:43:04.000Z. Sources: 4. Developments: 2.

Research led by neurologist Allal Boutjankout and NYU professor Thomas Wisniewski demonstrated that blood tests measuring plasma levels of beta-amyloid, tau, and inflammation-related proteins can identify Alzheimer’s disease biomarkers. The study indicated these markers could signal disease onset eight to ten years before clinical symptoms appear, potentially offering a lower-cost alternative to PET scans.

Following these developments, the U.S. Food and Drug Administration (FDA) cleared several blood tests for Alzheimer’s detection. C2N Diagnostics received approval for the PrecivityAD2 test, which uses mass spectrometry to measure amyloid and tau proteins. Clinical studies reported a 97.6% accuracy rate, and the test is available for individuals aged 40 and older experiencing cognitive complaints.

Additionally, the FDA cleared the Elecsys pTau-217 test, a collaboration between Roche and Eli Lilly. Designed for individuals aged 55 and older showing signs of cognitive decline, it is the first test to measure a single biomarker, plasma phosphorylated tau 217, and is compatible with over 4,500 analyzers across the United States. These advancements follow a previous 2025 clearance of a Fujirebio Diagnostics test. While these tests offer a less invasive alternative to spinal fluid exams and PET scans, medical experts note they should not be used as a “sole definitive diagnosis without clinical context.”

## Claims

- The FDA cleared the Elecsys pTau-217 blood test for individuals aged 55 and older showing signs of cognitive decline. (corroborated by 2 sources)
- Fujirebio Diagnostics received FDA approval for a test measuring both pTau217 and another protein. (corroborated by 2 sources)
- The FDA approved the PrecivityAD2 blood test for individuals aged 40 and older with cognitive complaints. (single source)
- The PrecivityAD2 test achieved an accuracy rate of 97.6 percent in clinical validation studies involving 142 adults. (single source)
- The Elecsys pTau-217 test is the first to measure a single biomarker to assess Alzheimer's. (single source)
- The Elecsys pTau-217 test can be used on more than 4,500 analyzers across the United States. (single source)

## Timeline

### 2026-08-26: FDA clears two new blood tests for Alzheimer's detection

The FDA has cleared two new blood tests, PrecivityAD2 and Elecsys pTau-217, to detect Alzheimer's biomarkers, providing a less invasive diagnostic option for patients with cognitive decline.

4 sources. https://clstr.news/cluster/fda-approves-two-new-blood-tests-for-alzheimers-detection

### 2026-08-07: Allal Boutjankout's Blood Test Enables Early Alzheimer's Detection

Moroccan scientist Allal Boutjankout and NYU’s Thomas Wisniewski developed a blood test that detects Alzheimer’s biomarkers up to a decade before symptoms, offering a low‑cost early‑diagnosis tool.

3 sources. https://clstr.news/cluster/allal-boutjankouts-blood-test-enables-early-alzheimers-detection

---
Cite as: Advancements in Alzheimer's blood test detection. CLSTR, https://clstr.news/situations/advancements-in-alzheimers-blood-test-detection